Ipsen's Partner Inspiration Biopharmaceuticals Announces the Initiation of the Second Phase III Pivotal Clinical Study of OBI-1 in Congenital Hemophilia A With Inhibitors
11/28/2011 10:15:37 AM
PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN, ADR: IPSEY) today announced that its partner Inspiration Biopharmaceuticals, Inc. (Inspiration) has initiated the treatment of the first patient in the second of two pivotal studies from the OBI-1’s Accur8 clinical trial program. In this newly initiated clinical study, OBI-1, an intravenous recombinant porcine factor VIII (FVIII) product, will be evaluated for the treatment of individuals with congenital hemophilia A, who have developed inhibitory antibodies (inhibitors) against their human FVIII replacement therapy.
comments powered by